U.S. Markets closed

Vitro Diagnostics, Inc. (VODG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.39500.0000 (0.00%)
At close: 2:59PM EDT
Sign in to post a message.
  • D
    Before the
    Release No. 90048 / September 29, 2020
    The Securities and Exchange Commission announced the temporary suspension, pursuant to
    Section 12(k) of the Securities Exchange Act of 1934, of trading in the securities of Vitro
    Diagnostics, Inc. (“VODG”) (CIK No. 0000793171), of Golden, CO, commencing at 9:30 a.m.
    EDT on September 30, 2020, and terminating at 11:59 p.m. EDT on October 13, 2020.
    The Commission temporarily suspended trading in the securities of VODG due to a lack of
    current and accurate information about the company because it has not filed certain periodic
    reports with the Commission.
    The Commission cautions broker-dealers, shareholders, and prospective purchasers that they
    should carefully consider the foregoing information along with all other currently available
    information and any information subsequently issued by the company.
    Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the
    Exchange Act, at the termination of the trading suspension, no quotation may be entered unless
    and until they have strictly complied with all of the provisions of the rule. If any broker or dealer
    has any questions as to whether or not it has complied with the rule, it should not enter any
    quotation but immediately contact the staff in the Division of Trading and Markets, Office of
    Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is
    required by Rule 15c2-11, it should refrain from entering quotations relating to VODG’s
    securities until such time as it has familiarized itself with the rule and is certain that all of its
    provisions have been met. If any broker or dealer enters any quotation which is in violation of
    the rule, the Commission will consider the need for prompt enforcement action.
    If any broker-dealer or other person has any information that may relate to this matter, they
    should immediately contact Sheldon L. Pollock, Assistant Regional Director, at 212-336-1100.
    The Commission appreciates the assistance of the Financial Industry Regulatory Authority
  • T
    The quarterly is out. Very little to note, except that it appears that there will be some additional dilution -- the $1 million offering was filled, and they are expanding it to $3.5 million. This is pretty much as expected, since their revenues have fallen off a cliff with the pandemic, and they need money to continue down the path they initiated. On the bright side, they expect a revenue storm as soon as the Cayman operation reopens, as there is a backlog of patients who want treatment. The report does not mention the SEC action, or if/how they will address it directly in the near term, but continues to state that they will be returning to full reporting by January. There is essentially no new information on the FDA applications for COVID-19 studies, and no color on the relationship with GIOSTAR. Overall, pretty much what I would expect, although it would have been nice to see some unexpected positive in there. If I missed anything in that category, please correct me.
  • T
    While we await news, I thought this would be a good time to commend Dr. Zamora for the quality of the Infinivive MD web site. It has grown up quite a bit over the past year or so, and stands in stark contrast to the sad joke that is GIOSTAR's site. I look forward to hearing some positive news from this side of the VODG business, as it has every appearance of being a real business, executed in a competent, professionally respectable way, with huge growth potential.
  • T
    The person running this study, Dr. Kurtzberg, spoke passionately at MESO's recent meeting at the FDA for aGVHD. I got the feeling that her testimony factored heavily in the decision to recommend approval. It appears that she is at it again. In some perfect world, it would be nice for VODG / Dr. Musick to develop a working relationship with her, if one doesn't exist. She is doing great work, saving lives, and seems to have a lot of credibility. Of course, I "simply don't know what I'm talking about", so do read my meanderings with a dose of healthy skepticism.
    FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) - read this article along with other careers information, tips and advice on BioSpace
    FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) - read this article along with other careers information, tips and advice on BioSpace
  • K
  • G
    Hey Guys, what happened to this stock? Back at 38 cents after some wild rides. I would think it would still be around 70 cents while we wait for news. Any one know when we can expect updates? Anything from FDA COVID approval etc?
  • D
    The decline in business because of C-19 are not discretionary "items", so as one looks at the quarterly figures, keep this very important fact in mind.
  • J
    SAN DIEGO (Legal Newsline) – A cancer patient who complained she was misled into thinking stem cell therapy would work failed to present any evidence in her lawsuit, says the Global Institute of Stem Cell Therapy and Research.
    SAN DIEGO (Legal Newsline) – A cancer patient who complained she was misled into thinking stem cell therapy would work failed to present any evidence in her lawsuit, says the Global Institute of Stem Cell Therapy and Research.
  • D
    Trading Halted? No Bid no Ask.
  • K
    Do not feed the trolls. It causes the nonsense that they write to be elevated to "Top Reactions" because of the responses they generate. I find putting them immediately on ignore (mute) is the way for me, at least, to take care of them. If they think the stock is going to zero then they don't have to buy it. And many of these people are kids or at least act like them.
  • T
    MESO's COVID-19 study gets the go-ahead to finish. I do not have a lot of experience with these things, so I assume this is mildly good news -- I interpret it to mean that the early read-out is good enough to continue, but not such a slam dunk that more data are not warranted. If anyone else has a better real-world interpretation, please chime in.
  • G
    Looking like it was building up for a pop over the last week or so and the bottom just fell out on 150,000 volume???
  • D
    Had an extremely interesting and deeply informative conversation with VODG management and consultant(s) yesterday.
  • F
    Loving that phase 1 trial with 20 patients, that is underway.
  • D
    NITE and GTSM are currently offering stock at .41. I just purchased 2,500 at .41; NITE still offering 2,500 at .41, GTSM 2,500 at .42 then CDEL 3,600 at .50. All of this changes with the flow of the day.
  • D
    regenerative medicine market, but also to play a pivotal role in driving the growth of the
    market. Our DCF model indicates that Vitro is worth at least ~4X its current OTC market value, with a fair value target range of $1.70-$4.44 on a fully-diluted basis. This substantial valuation gap is confirmed when comparing Vitro with some of its stem cell peers. Success with its IND submission to the FDA and moves towards becoming a fully reporting company, expected to be current in 1Q 2021 would, in our view, go a long way towards narrowing Vitro’s valuation gap sooner rather than later.

    Pathway to explosive growth and high returns

    While the ongoing Covid-19 pandemic is expected to temporarily disrupt Vitro’s rapid growth trajectory this year, we anticipate a return to revenue growth in FY 2021 and beyond, enabling the company to turn EBITDA positive next year. Based on Vitro’s growth initiatives, we believe that its revenue has the potential to rise to $45-$50MN in the next 5 years from the just under $1MN
    recorded in the past 12 months, driven by the expansion of several strategic partnerships in the medical tourism market and the continued growth of its premium antiaging cosmetic and nutraceutical products. Moreover, given that its scalability requires relatively low capital,
    Vitro has the capacity to deliver highly profitable revenue growth

    • Allogeneic adult stem cell technology gaining wider
    acceptance driven by growing demand for regenerative
    • Vitro boasts an experienced science and operating
    management team.
    • Vitro’s AlloRx® umbilical cord harvested MSC stem cells
    meet or exceed all benchmark ISCT international stem
    cell standards.
    • AlloRx® stem cells, which have been used in over 100
    anti-aging and inflammatory treatments for clinical
    trials in strictly regulated offshore clinics with no
    adverse events, is developing a growing body of
    evidence to support their safety and efficacy.
    • A uniquely scalable manufacturing process from an
    ISO9001 13485, CLIA certified cGMP, FDA registered
    facility, which can harvest 5 Trillion stem cells from
    one umbilical cord, potentially generating over
    $85MN in AlloRx® revenues. Vitro’s current potential
    capability with its 1,000 sq.ft. clean room can produce
    300 BN stem cells per year for 3,000 therapies
    producing $5MN of annual revenue to Vitro. Vitro
    plans to expand into its second clean room during
    the third quarter of 2020, with two additional clean
    rooms expected to be established by 2025.
    • Vitro is close to getting FDA approval for a Phase I
    clinical trial for Covid-19 which will open the door
    for INDs covering treatment of other inflammatory
    conditions in the US.
    • Active patent program to protect revenue and provide
    flexibility to operate around the world.
    • Scalability and relatively low capital needs gives Vitro
    the capacity to deliver revenue growth with growing
    profitability — Vitro to turn EBITDA positive in FY 2021
    and free cash flow positive in FY 2022.

    Multiple Revenue Streams
    & Expanding Opportunities
    • Vitro is starting to generate multiple revenue streams as 10 years of R&D come to fruition — the company hasdelivered almost $1MN in revenue over the past 12 months, a fivefold increase on FY 2016. We project revenue to rise to $45-$50MN in the next 5 years, with substantially more
    upside should the FDA open up the US market to Vitro’s technology for clinical applications.
    • AlloRx® stem cells and growth medium MSC-Gro™ are already being used in the treatment of inflammatory and neurodegenerative indications such as Multiple Sclerosis,OsteoArthritis, Stroke,Lyme Disease, Crohn's, COPD,Autism, Alzheimer's and Parkinson’s in offshore clinics. Expansion of existing offshore strategic partnerships led byDVC Stem in the Caymans (www.dvcstem.com), the MedicalPavilion of the Bahamas (www.tmp-bahamas.com)
    and Australia’s Magellan (www.magellanstemcells.com.au)along with the targeted addition of new partnerships is expected to conservatively drive revenues from AlloRx®/MSC-Gro™ from ~$200K in FY 2019 to ~$11MN by FY 2025.Access to the US clinical market will provide significant
    upside to this number.
    • InfiniVive MD™ (www.infinivive.com), the world’s first cosmetic post-operative stem cell serum for topicalapplication developed and marketed in an exclusive partnership with Dr. Jack Zamora (www.jackzamoramd.com),has already enjoyed rapid penetration, delivering almost$0.5MN of revenue within the first year of its launch inlate 2018. Revenue from InfiniVive MD™ is expected tocontinue to increase its market reach expanding revenueto more than $20MN by 2025.
    • STEMulize™, a nutraceutical stem cell activator, a new product formulated by Vitro, is expected to be launched next year with its marketing strategy leveraged to InfiniVive MD™. We project STEMulize™ to contribute $12MN by 2025.
    • We expect baseline operations of cell culture media and other research products sold to world renown...
  • T
    Let's all rejoice that August is coming to a merciful close. We need another news cycle. And that should come soon, courtesy of our MESO friends. And the next VODG quarterly will not be too far behind. And if we see another compassionate use success in there somewhere, all the better. Better times ahead.
  • D
    The following is just a part of a long, detailed report written for the novice as well as the professional. I have spent a great deal of time copying and pasting.

    If you want more try the research company's website.
  • J
    GOLDEN, Colo. (KDVR) — Stem cells from a lab in Golden gave a COVID-19 patient near death a second chance at life. “First you have to thank God, but then you have to thank the ste…
    GOLDEN, Colo. (KDVR) — Stem cells from a lab in Golden gave a COVID-19 patient near death a second chance at life. “First you have to thank God, but then you have to thank the ste…
  • K
    So this is interesting....
    Stem cells via atomized nebulizer. If you're a "Med Head" you know other drugs like Epi or Narcan can be given Intranasal as well as IM or IV.... But stem cells???
    The research team at Abu Dhabi Stem Cell Centre. A revolutionary stem cell therapy administered through a nebuliser successfully treated 73 COVID-19 patients in the initial clinical trials. As of June 26, 2020, more than 2,000 patients suffering from COVID-19 had been treated with stem cell therapy (SCT) by the Abu Dhabi Stem Cell Centre (ADSCC). Of that number, 1,200 already fully recovered from the effects of the disease.
    2 promising therapies among weapons dispatched against coronavirus
    2 promising therapies among weapons dispatched against coronavirus